Ignite Creation Date:
2024-05-05 @ 11:28 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00048165
Status:
COMPLETED
Last Update Posted:
2016-06-13
First Post:
2002-10-24
Brief Title:
A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept Cyclosporine and Corticosteroids in Patients Undergoing Cardiac Transplantation
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Study Overview
Official Title:
A Double-Blind Placebo -Controlled Randomized Study to Assess the Efficacy and Safety of Zenapax in Combination With CellCept Cyclosporine and Corticosteroids in Patients Undergoing Cardiac Transplantation
Status:
COMPLETED
Status Verified Date:
2016-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to compare the number of randomized participants in each treatment group who experience an acute rejection episode in the first 6 months after undergoing cardiac transplantation
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None